Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: You all sites on hold. We appreciate your patience, and please continue to stand by. All sites on hold. We appreciate your patience, and ...

1 Department of Surgery, Queen Elizabeth Hospital 2, Kota Kinabalu, Sabah. 2 Department of Pathology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah. 3 Department of Surgery, Faculty of Medicine and ...

(MENAFN- GlobeNewsWire - Nasdaq) - Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with ...

SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

Overall response rates with immune checkpoint inhibitors were high in patients with pleomorphic dermal sarcoma and cutaneous angiosarcoma. The efficacy of systemic therapy varies among patients with ...

Sarcomas of the head and neck are rare malignant tumors accounting for less than 1% of malignant tumors in this region and less than 10% of all soft tissue sarcomas. Head and neck sarcomas are mainly ...

Did Apple Cider Vinegar’s Milla Blake, Lucy Guthrie, and Justin find hope or tragedy in their journeys? Netflix’s limited series unravels the shocking story of Belle Gibson, an Australian influencer ...

INVINCIBLE-3 Study continues to recruit patients with leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., ...